Pliant Therapeutics, Inc. (PLRX)
- Previous Close
13.81 - Open
13.95 - Bid 13.59 x 100
- Ask 13.70 x 100
- Day's Range
13.32 - 14.00 - 52 Week Range
11.21 - 24.74 - Volume
213,548 - Avg. Volume
345,764 - Market Cap (intraday)
823.447M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-2.86 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.08
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
pliantrx.comRecent News: PLRX
Performance Overview: PLRX
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLRX
Valuation Measures
Market Cap
833.10M
Enterprise Value
405.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.33k
Price/Book (mrq)
1.90
Enterprise Value/Revenue
1.63k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.71%
Return on Equity (ttm)
-34.17%
Revenue (ttm)
248k
Net Income Avi to Common (ttm)
-170.74M
Diluted EPS (ttm)
-2.86
Balance Sheet and Cash Flow
Total Cash (mrq)
482.39M
Total Debt/Equity (mrq)
12.50%
Levered Free Cash Flow (ttm)
-68.27M
Research Analysis: PLRX
Company Insights: PLRX
PLRX does not have Company Insights